Wang Min, Ma Haifen
Department of Pathology, Beilun People's Hospital, Ningbo, Zhejiang 315800, P.R. China.
Mol Clin Oncol. 2016 Aug;5(2):323-326. doi: 10.3892/mco.2016.935. Epub 2016 Jun 14.
It has been suggested that Paired box gene (PAX)2 is activated by estradiol via estrogen receptor (ER)α in breast and endometrial cancer. The expression of PAX2 was restricted to ovarian serous tumors and only one case was positive in borderline mucinous tumor in our previous study. In the present study, immunohistochemistry was performed to assess the expression of ERα in 58 cases of ovarian serous tumors, including 30 serous cystadenomas, 16 borderline serous cystadenomas, 12 serous carcinomas and 67 cases of ovarian mucinous tumors, including 29 mucinous cystadenoma, 23 borderline mucinous cystadenoma and 15 mucinous carcinoma, which were the same specimens with detection of PAX2 expression. The results demonstrated that ERα was expressed in 10% (3/30) of serous cystadenomas, 62.5% (10/16) borderline serous cystadenomas and 66.7% (8/12) serous carcinomas. The expression of ERα in borderline serous cystadenomas and serous carcinomas were significantly higher compared with that in serous cystadenomas (P<0.01). ERα was detected in 3.4% (1/29) mucinous cystadenoma, 26.1% (6/23) borderline mucinous cystadenoma and only 6.7% (1/15) mucinous carcinoma. Furthermore, a scatter plot of the expression of PAX2 and ERα revealed a linear correlation between them in ovarian serous tumors (P<0.0001). With few positive results, no correlation was determined in ovarian mucinous tumors. It was demonstrated that PAX2 is associated with ERα in ovarian serous tumors, and this may become a potential theory basis for targeted therapy for ovarian serous tumors. Further research is required to determine how PAX2 and ERα work together, and the role of targeted therapy in ovarian serous tumors.
有人提出，在乳腺癌和子宫内膜癌中，配对盒基因（PAX）2通过雌激素受体（ER）α被雌二醇激活。在我们之前的研究中，PAX2的表达仅限于卵巢浆液性肿瘤，在交界性黏液性肿瘤中只有1例呈阳性。在本研究中，采用免疫组织化学方法评估58例卵巢浆液性肿瘤中ERα的表达，其中包括30例浆液性囊腺瘤、16例交界性浆液性囊腺瘤、12例浆液性癌，以及67例卵巢黏液性肿瘤，其中包括29例黏液性囊腺瘤、23例交界性黏液性囊腺瘤和15例黏液性癌，这些均为检测PAX2表达的相同标本。结果显示，ERα在30例浆液性囊腺瘤中的表达率为10%（3/30），在16例交界性浆液性囊腺瘤中的表达率为62.5%（10/16），在12例浆液性癌中的表达率为66.7%（8/12）。交界性浆液性囊腺瘤和浆液性癌中ERα的表达明显高于浆液性囊腺瘤（P<0.01）。在29例黏液性囊腺瘤中ERα的检出率为3.4%（1/29），在23例交界性黏液性囊腺瘤中为26.1%（6/23），在15例黏液性癌中仅为6.7%（1/15）。此外，PAX2和ERα表达的散点图显示，在卵巢浆液性肿瘤中它们之间存在线性相关性（P<0.0001）。由于阳性结果较少，在卵巢黏液性肿瘤中未确定相关性。结果表明，在卵巢浆液性肿瘤中PAX2与ERα相关，这可能成为卵巢浆液性肿瘤靶向治疗的潜在理论基础。需要进一步研究以确定PAX2和ERα如何共同发挥作用，以及靶向治疗在卵巢浆液性肿瘤中的作用。
